Decoding Protein Interfaces, Accelerating Discovery

RubrYc Therapeutics, Inc., is a biotechnology solutions company using disruptive innovation to deliver fresh insights into the design and development of therapeutic antibodies. Inspired by recent advancements in molecular library synthesis, massively parallel screening and computing, we are forging a new path for information-driven discovery of therapeutic antibodies. Using our RubrYc Discovery Engine, we can decode protein interactions through the integration of data and biological science. This interface-targeted approach allows RubrYc to accelerate pre-clinical therapeutic antibody discovery, while minimizing many of the risks associated with current drug discovery paradigms.

Founded in 2017, RubrYc Therapeutics, Inc. emerged as the exclusive biotherapeutic partner of immunomics leader HealthTell. In March 2018, RubrYc Therapeutics, Inc., spun out of HealthTell to define its trailblazing role in the growing field of immunomics. RubrYc leverages our Discovery Engine technology to advance proprietary discovery programs and to partner with top-tier pharmaceutical companies that share our drive to innovate the discovery of therapeutic antibodies.

RubrYc Therapeutics is a trusted drug discovery partner, and thrives on your success.

We Promise Accountability

From data quality to on-time reporting, we follow through on our commitments. We are passionate about the impact of our technology, guiding discovery of new therapies for our partners and patients in need.

We Value Reliability

We practice science with rigor and consistency. We provide our partners dependable, actionable results.

We Offer Flexibility

We provide multiple antibody discovery services for partner-supplied mAbs, including: functional epitope mapping, immunization strategy and immunogen design, and on- and off-target binding prediction.

We Create Value

When a partner specifies drug targets to launch discovery campaigns, we efficiently deploy resources throughout the discovery process to deliver de-risked and demonstratively efficacious drug candidates.